← Leaderboards
Raghu Ganugula
Texas A&M University
$747,813
Attributed
$1,495,625
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $378.1K · FY2020–23$500K$375K$250K$125K$0
'20
'21
'22
'23
Funding mix
By agency
NIH$1,495,625 · 1
By mechanism
R01$1,495,625 · 1
Top collaborators
- Ravikumar N Majeti4 shared
Most similar at Texas A&M University
Same institution · by research overlap
- Richard H Gomer$9,835,941
- Quentin N Michaudel$713,874
Others in their field
Other Emerging Leaders on “Active Biological Transport”
- Kevin William Riley · University Of California Los Angeles$13,198,487
- James Dale Berry · Brigham And Women'S Hospital$9,298,517
- Leonard Freedman · Leidos Biomedical Research, Inc.$8,389,601
- Christopher Bates · University Of California-Santa Barbara$8,007,068
- Sunyoung Kim · Louisiana State University Health Sciences Center$7,492,070
- Sebastien Boutet · Stanford University$7,337,028
Research focus
Active Biological TransportAbsorptionAffectAffinityAmphiphilicityAdoptionAnxietyApicalApoptosisBeta CellBindingBinding SitesAnalogBiodistributionBiologicalBiological AvailabilityBiological ModelsBlood GlucoseCapsuleCarbohydratesCardiovascular Disorder RiskCell LineCell PhysiologyCell Surface
Grant awards (4)
Oral delivery of insulin using ligand-directed nanoparticles that do not compete with physiological ligands$372,500
R01 · FY2023 · DK
Oral delivery of insulin using ligand-directed nanoparticles that do not compete with physiological ligands$372,500
R01 · FY2022 · DK
Oral delivery of insulin using ligand-directed nanoparticles that do not compete with physiological ligands$372,500
R01 · FY2021 · DK
Oral delivery of insulin using ligand-directed nanoparticles that do not compete with physiological ligands$378,125
R01 · FY2020 · DK